NCT03193398 - BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

June 12, 2017

Primary Completion Date

November 12, 2018

Study Completion Date

December 12, 2018

Conditions

Major Depressive Disorder

Interventions

DRUG

BTRX-246040 oral capsule(s)

BTRX-246040 administered once daily to patients with MDD for 8 weeks

DRUG

Placebo oral capsule(s)

administered once daily to patients with MDD for 8 weeks

Trial Locations (8)

United States, Rochester

United States, Florida, Jacksonville

United States, Florida, Orlando

United States, Lauderhill

United States, Memphis

United States, Libertyville

United States, Cerritos

United States, Garden Grove